Last reviewed · How we verify
DOBUTamine Injectable Solution
Dobutamine is a beta-1 adrenergic agonist that increases cardiac contractility and heart rate to improve cardiac output.
Dobutamine is a beta-1 adrenergic agonist that increases cardiac contractility and heart rate to improve cardiac output. Used for Acute decompensated heart failure with reduced cardiac output, Cardiogenic shock, Low cardiac output states requiring inotropic support.
At a glance
| Generic name | DOBUTamine Injectable Solution |
|---|---|
| Also known as | Dobutamine |
| Sponsor | The Young Investigator Group of Cardiovascular Research |
| Drug class | Beta-1 adrenergic agonist |
| Target | Beta-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Dobutamine selectively stimulates beta-1 adrenergic receptors on cardiac myocytes, increasing the force of myocardial contraction (positive inotropic effect) and heart rate (positive chronotropic effect). This results in increased cardiac output and improved perfusion to vital organs. It is used acutely in patients with reduced cardiac output due to heart failure or cardiogenic shock.
Approved indications
- Acute decompensated heart failure with reduced cardiac output
- Cardiogenic shock
- Low cardiac output states requiring inotropic support
Common side effects
- Tachycardia
- Hypertension
- Arrhythmias
- Headache
- Tremor
- Chest pain
Key clinical trials
- Effect of TEE-guided Non-fluid Limited Combined With Dobutamine on Hepatic Venous Blood Flow Spectrum (EARLY_PHASE1)
- Ivabradine Effects in Cardiogenic Shock Requiring Inotropic Support (PHASE3)
- Levosimendan In Patients Undergoing LVAD Implantation
- Non-invasive Early Goal Directed Therapy in Colorectal Surgery: a Feasibility Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: